CD33 and acute myeloid leukemia: For instance, preclinical data suggests Siglec-6 could also be a suitable CAR T target in AML, since it is widely expressed on AML blasts as well as LSC, yet not on HSC or hematopoietic progenitor cells, unlike other Siglec-family members such as Siglec-3 (i.e. CD33) (49).